
Dr. Ruby Yonghong TANG, Founder of Taikomed Pharmaceutical Group
Tang Yonghong, female, member of China Farmers and Workers Democratic Party. Licensed pharmacist, Senior engineer, Chairman and General manager of Taikomed Pharmaceutical Group.
Educational background
· Bachelor of Pharmacy, Clinical Medicine. University of Traditional Chinese Medicine
· Master of Business Administration (MBA), Northwestern University
· Doctor of Health Management (DHM), University of Montpellier, France.
Social Position
· Visiting professor of Xi 'an Medical University
· Master tutor of Graduate School of Northwest University
Honor and Qualification
· National Federation of Industry and Commerce Chamber of Medicine "2022-2023 to promote the high-quality development of the pharmaceutical and health industry TOP100 people"
· Shaanxi Economic Development Promotion Association "2023-2024 Shaanxi Top ten economic people".
Business overview of the company
Founded the Taikomed Pharmaceutical Group, built a full chain, all-round, the whole process of one-stop medical research and development service chain, under the 3 drug and device research and development center, 1 MAH transformation and service platform, 1 MAH drug sales platform.
1.1 Drug and device Research and development Center
(1) R&D center for innovative drugs and devices
· Innovative drugs: Focusing on mental diseases, cardiovascular and cerebrovascular diseases, anti-tumor fields, the field of chronic diseases to establish a differentiated and competitive R & D pipeline, the core products have been in the clinical trial stage.
· Medical device CRO: clinical trial, registration, quality management system
· Medical device CDMO: R & D, design, commissioned production
(2) CRO drug development service platform
· Innovative drug CMC and clinical research services
· API related declaration and intermediate CDMO services
· Generic drugs and generic drug consistency evaluation
· Traditional Chinese medicine innovative medicine, the same name medicine, classic famous prescription, large varieties of secondary development, big health product development
· Class III medical device product development and registration
(3) High-end preparation development platform
Improved New drug /505(b)(2) development
Characteristic preparation technology platform
· High-end oral preparations: technology platform for slow controlled release, solid dispersion, new particle system drug delivery, etc
· Complex liquid preparations: microspheres, liposomes, in situ gels, microcrystals, polyethylene glycol modification, etc
1.2 MAH conversion and service platform
· MAH certified product development
· MAH drug licensed conversion
· MAH Quality management system
· Product quality improvement services and GMP consulting
· Pharmacovigilance and evidence-based study after marketing
1.3 MAH drug sales platform
· Establish a joint certificate holding platform
· Joint development property rights share common interests
2. Social duties
· Chairman of the Medicine Branch of Shaanxi Provincial Committee of Chinese Peasants and Workers Democratic Party
· Deputy Director of Economic Work Committee of Shaanxi Provincial Committee of Chinese Peasants and Workers Democratic Party
· Tutor for postgraduate students of Northwest University
· Visiting Professor, Xi 'an Medical College
· Science and Technology consultant of Xi 'an High-tech Zone
· Ankang City attracts talents and experts